Bausch + Lomb is an eye health company that develops and distributes contact lenses, pharmaceutical treatments, and surgical devices across multiple markets globally. The company operates in three primary segments: Vision Care, which includes daily disposable and therapeutic contact lenses along with lens care products and over-the-counter eye drops; Pharmaceuticals, encompassing proprietary and generic medications for conditions including glaucoma, dry eye, ocular inflammation, and retinal diseases; and Surgical, offering equipment, consumables, and devices for cataract and corneal procedures, including intraocular lenses and phacoemulsification systems.
The company maintains a significant operational footprint with approximately 13,000 full-time employees and operates across North America, Europe, and Asia-Pacific regions, including presence in the United States, Canada, China, Japan, Germany, the United Kingdom, France, and other markets. Products are distributed through both direct sales forces and independent distributors. Bausch + Lomb is headquartered in Vaughan, Ontario, Canada and operates as a subsidiary of Bausch Health Companies Inc. The company traces its origins to 1853, reflecting substantial tenure in the ophthalmology sector.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-1.02 | $-1.02 | -13.3% | |
| 2024 | $-0.90 | $-0.90 | -21.6% | |
| 2023 | $-0.74 | $-0.74 | -3800.0% | |
| 2022 | $0.02 | $0.02 | — |